Stover Daniel G, Salgado Roberto, Savenkov Oleksander, Ballman Karla, Mayer Erica L, Magbanua Mark Jesus M, Loi Sherene, Vater Mark, Glover Kristyn, Watson Mark, Wen Yujia, Symmans W Fraser, Perou Charles, Carey Lisa A, Partridge Ann H, Rugo Hope S
Division of Medical Oncology, Department of Medicine, The Ohio State University College of Medicine, Columbus, OH, USA.
Pelotonia Institute for ImmunoOncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
NPJ Breast Cancer. 2024 Aug 21;10(1):75. doi: 10.1038/s41523-024-00683-x.
Association of stromal tumor-infiltrating lymphocytes (sTILs) with survival outcomes among patients with metastatic breast cancer (MBC) remains unclear. The primary objective was to evaluate the association of sTILs with progression-free survival in randomized phase III trial CALGB 40502. sTILs were associated with progression-free and overall survival in chemotherapy-treated MBC when controlling for treatment arm; however, this effect did not remain significant after additional adjustment for hormone receptor status. CALGB is now part of the Alliance for Clinical Trials in Oncology. Trial Registration: ClinicalTrials.gov: NCT00785291.
基质肿瘤浸润淋巴细胞（sTILs）与转移性乳腺癌（MBC）患者生存结局之间的关联仍不清楚。主要目的是在随机III期试验CALGB 40502中评估sTILs与无进展生存期的关联。在控制治疗组的情况下，sTILs与接受化疗的MBC患者的无进展生存期和总生存期相关；然而，在对激素受体状态进行额外调整后，这种效应不再显著。CALGB现在是肿瘤学临床试验联盟的一部分。试验注册：ClinicalTrials.gov：NCT00785291。
